The management of hormone-relapsed prostate cancer

Comment

. 2004 May;93(7):1115.

doi: 10.1111/j.1464-410X.2004.4834b.x.

Comment

R W Parkinson et al. BJU Int. 2004 May.

. 2004 May;93(7):1115.

doi: 10.1111/j.1464-410X.2004.4834b.x.

No abstract available

Comment on

The management of hormone-relapsed prostate cancer.
Clarke NW. Clarke NW. BJU Int. 2003 Nov;92(8):860-8. doi: 10.1046/j.1464-410x.2003.04494.x. BJU Int. 2003. PMID: 14616436 Review. No abstract available.

The management of hormone-relapsed prostate cancer.
Clarke NW. Clarke NW. BJU Int. 2003 Nov;92(8):860-8. doi: 10.1046/j.1464-410x.2003.04494.x. BJU Int. 2003. PMID: 14616436 Review. No abstract available.
Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
Ghosn M, Kattan J, Younes F. Ghosn M, et al. Tunis Med. 2005 Dec;83 Suppl 12:74. Tunis Med. 2005. PMID: 16430073 No abstract available.
Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A. Koutsilieris M, et al. BJU Int. 2007 Jul;100 Suppl 2:60-2. doi: 10.1111/j.1464-410X.2007.06958.x. BJU Int. 2007. PMID: 17594363 Review. No abstract available.
Hormone-refractory prostate cancer: what have we learned?
Wirth MP. Wirth MP. BJU Int. 2007 Jul;100 Suppl 2:56-9. doi: 10.1111/j.1464-410X.2007.06957.x. BJU Int. 2007. PMID: 17594362 Review. No abstract available.
Editorial: hormone therapies for prostate cancer--acute disease control, chronic disease progression.
Lamb DJ, Buttyan R. Lamb DJ, et al. J Urol. 2003 Apr;169(4):1558. doi: 10.1097/01.ju.0000056992.26783.33. J Urol. 2003. PMID: 12629414 No abstract available.